Illumina (ILMN) announced it is collaborating with Nvidia (NVDA) to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research, genomics AI development, and drug discovery. To optimize analysis of the vast amounts of data involved in multiomic research, Illumina and Nvidia will combine advancements in AI with multiomic data at scale. Leveraging Illumina’s leading sequencing technology and informatics tools alongside Nvidia’s leading AI technology, the partnership aims to accelerate drug discovery and clinical development, delivering powerful tools to help pharmaceutical companies identify new and better drug targets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Nvidia enters partnerships in healthcare, life sciences industry
- Regeneron announces strategic collaboration with Truveta
- Illumina launches pilot proteomics program with UK Biobank, collaborators
- Illumina price target lowered to $140 from $145 at Bernstein
- Illumina launches update to its NovaSeq X Series software
Questions or Comments about the article? Write to editor@tipranks.com